Moderna says updated Covid vaccine was effective against highly mutated BA.2.86 variant in trial

Moderna's updated Covid vaccine has shown a strong immune response against the highly mutated omicron variant BA.2.86, suggesting that the vaccine will still be effective against newer variants of the virus.

cnbc.com

Relevant topic timeline:

8/27/2023

Covid cases are rising, just as new vaccines are almost ready

The U.S. is experiencing a rise in Covid cases just as new vaccines that protect against the latest variants are almost ready.

9/7/2023

Some good COVID news: New vaccine appears to work well against Pirola subvariant

The new COVID-19 vaccine from Moderna appears to provide strong protection against the highly mutated BA.2.86 subvariant, according to updated vaccine data, offering reassurance as manufacturers and public health officials continue to combat the evolving coronavirus.

9/8/2023

Early data suggests existing antibodies protect against new COVID variant BA.2.86, even as FDA prepares to authorize updated vaccines

Antibodies from prior infection or existing vaccines are effective against the BA.2.86 variant, and the increase in COVID cases in the US is not driven by this variant, according to the CDC.

9/11/2023

FDA authorizes new Omicron-targeting COVID boosters from Pfizer, Moderna; shots could be available within days pending CDC approval.

Two new Covid shots from Pfizer-BioNTech and Moderna have been approved by the FDA and are expected to be available soon as cases continue to rise in some parts of the US, with preliminary research suggesting they offer protection against the dominant variant and other concerning variants.

9/11/2023

FDA Approves Updated COVID Boosters for Fall, Including for Babies 6 Months and Up

The FDA has approved updated COVID-19 vaccine and booster shots, targeting new variants, and making them available for Americans as young as 6 months old from Moderna and Pfizer.

9/11/2023

FDA Approves Updated Pfizer, Moderna COVID Boosters Targeting XBB.1.5 Omicron Subvariant

The US FDA has approved new COVID booster shots from Pfizer and Moderna to address the omicron subvariant XBB.1.5, which could be available in the coming days pending CDC clearance.

9/13/2023

Moderna's mRNA Flu and RSV Vaccines Show Promise in Latest Trial Data

Moderna's experimental mRNA-based seasonal flu vaccine, mRNA-1010, demonstrated a stronger immune response against four strains of the flu virus compared to a currently marketed vaccine, paving the way for potential approval from regulators.

9/13/2023

Updated COVID Boosters With Omicron Target Now Available, But Demand Uncertain

Americans can now receive an updated COVID-19 vaccine to reduce the severity of symptoms, protect against current variants, and curb the risk of "long COVID."

9/13/2023

Moderna's New Flu Vaccine Shows Stronger Immune Response Than Traditional Shots in Late-Stage Trial

Moderna's flu vaccine has demonstrated a stronger immune response against all strains of the influenza virus compared to traditional flu shots, potentially allowing the company to file for accelerated approval in the US by year-end and launch the vaccine for the 2024/2025 season, while also scaling down its COVID-19 vaccine manufacturing to meet lower post-pandemic demand.